7 November 2019
IQ-AI LIMITED
(“IQ-AI” or the “Company“)
Initiation of IB Stroke Project
IQ-AI announces that a series of new technology initiatives are being launched that will form the backbone for the Company’s new products as well as enhancements to existing products during calendar 2020. These advancements are substantially derived from the progress being made with IQ-AI’s previously announced Gadolinium free product initiative.
Most notable of these initiatives is a project which we expect to complete in the final quarter of 2020, to leverage our existing algorithms to create an ‘IB Stroke’ package. One of the unique features of Imaging Biometrics’ (IB) portfolio of brain focused products is their ability to accurately map and quantify blood flow in the brain. IB already offers a unique biopsy-validated diagnostic imaging platform to neuroradiologists for assessing brain tumors and monitoring their response to treatment. IB also offers all the metrics found to be most valuable for the evaluation of stroke and response to therapies. For example, IB’s proven perfusion and diffusion maps will be used to generate the perfusion-diffusion mismatch (DPM) which typically represents ischemic penumbra, or the area of viable tissue at risk. IB will leverage its proven ability of efficiently translating novel developments into routine clinical use, to create an automated and streamlined processing application for clinician’s use.
There are two principal forms of stroke, hemorrhagic stroke and ischemic stroke. Hemorrhagic stroke results from ruptured blood vessels, ischemic stroke results from blocked blood vessels. Both have the effect of denying brain tissue sufficient blood flow, nutrients and oxygen to maintain its viability. The ability of IB’s suite of products to accurately track regional blood volume can be used to diagnose and project outcomes for stroke victims. With respect to MR processing, the commonly accepted pre-load dose of gadolinium could also be avoided with this product which is consistent with our longer-term goal of reducing and eliminating gadolinium-based contrast agents. Eliminating this pre-load dose of contrast agent for stroke assessment could potentially save valuable time which is absolutely critical for stroke patients.
In the USA, the Center for Disease Control (CDC) reports that annually 795,000 people have a stroke. Of these, 610,000 are new strokes and 87% are ischemic strokes, the remainder being hemorrhagic strokes. According to the CDC, “Stroke costs the United States an estimated $34 billion each year.1 This total includes the cost of health care services, medicines to treat stroke, and missed days of work,” and “Stroke is a leading cause of serious long-term disability. Stroke reduces mobility in more than half of stroke survivors age 65 and over.”¹
David Smith, COO of IQ-AI Ltd. commented “This initiative grew out of the solid progress we are making on our gadolinium free project and represents an area that is 30 times the size of that product opportunity. Further, it uses the diagnostic imaging techniques that are already in our FDA cleared IB suite of brain tumor focused products.”
¹https://www.cdc.gov/stroke/facts.htm
**ENDS**
For further information please contact:
IQ-AI Limited
Qu Li/Trevor Brown/Vinod Kaushal
Tel: 020 7469 0930
Peterhouse Capital Limited (Financial Advisor and Broker)
Lucy Williams and Heena Karani
Tel: 020 7469 0930
About IQ-AI Ltd
IQ-AI, Ltd, the parent company of StoneChecker® and Imaging Biometrics®, is focused on advanced and state of the art medical software and services. (IQ-AI.ltd). Imaging Biometrics develops and provides visualization and analytical solutions that enable clinicians to better diagnose and treat diseases with greater confidence. Through close collaboration with top researchers and clinicians, sophisticated advancements are translated into platform-independent software plug-ins which can extend the base functionality of workstations, imaging systems, PACS, or medical viewers. By design, IB’s advanced visualization software seamlessly integrates into routine workflows. Please visit www.imagingbiometrics.com for further information.
About Imaging Biometrics™, LLC
Imaging Biometrics, a subsidiary of IQ-AI Limited (LON: IQAI), develops and provides visualization and analytical solutions that enable clinicians to better diagnose and treat diseases with greater confidence. Through close collaboration with top researchers and clinicians, sophisticated advancements are translated into platform-independent software plug-ins which can extend the base functionality of workstations, imaging systems, PACS, or medical viewers. By design, IB’s advanced visualization software seamlessly integrates into routine workflows. For more information about Imaging Biometrics, visit the company’s website at www.imagingbiometrics.com.